Medtronic plc, a leader in medical technology, has announced receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Visualase™ V2 MRI-Guided Laser Ablation System. This clearance marks a significant advancement in the Visualase™ platform, enhancing its capabilities as a minimally invasive surgical option for treating conditions such as focal epilepsy, brain tumors, and radiation necrosis. With redesigned software and hardware, the V2 system offers improved precision, accuracy, and visualization, allowing for efficient workflows and real-time MRI guidance. This innovation promises reduced hospital stays, faster recovery, minimal scarring, lower infection risks, and high patient satisfaction.